使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, and welcome to the DexCom fourth quarter results conference call. Today's call is being recorded. At this time, all participants are in a listen-only mode. Following today's presentation, we will conduct a question- and-answer session. Instructions will be given at that time for you to queue up for your questions.
各位好,歡迎參加 DexCom 第四季財報結果電話會議。今天的會議將被錄音。目前所有與會者皆處於僅收聽模式。在今天的簡報結束後,我們將進行問答環節。屆時將提供排隊提問的指示。
And now, at this time, I would like to turn the conference over to the Chief Executive Officer, Andy Rasdal. Please go ahead.
現在,我想把會議交給執行長 Andy Rasdal。請開始。
Andy Rasdal - CEO
Andy Rasdal - CEO
Good afternoon. Thanks for joining us on our fourth quarter earnings call. To start, I'll just briefly cover the agenda. I would like to start out, as we typically do, with a financial review update on a variety of issues related to our commercialization, talk about reimbursement to our product pipeline, and a few various topics at the end and open up for questions.
各位下午好。感謝各位參加我們的第四季財報電話會議。首先,我先簡要說明議程。我想先如同往常一樣,從財務回顧開始,更新多項與我們商業化相關的議題,接著談到給付(reimbursement)與我們的產品研發管線,最後再補充幾個主題並開放提問。
So at this time, I would like to turn it over to Steve Kemper, our Chief Financial Officer.
那麼此刻,我想把時間交給我們的財務長 Steve Kemper。
Steve Kemper - CFO
Steve Kemper - CFO
Thanks, Andy, and good afternoon, everyone. First I'd like to remind everyone that we will be making forward-looking statements, so please refer to our 10-K, which we just filed, as well as all our other SEC disclosures for a full discussion of the risks.
謝謝你,Andy,各位下午好。首先提醒各位,我們將發表前瞻性陳述,因此請參閱我們剛提交的 10-K,以及我們其他所有向 SEC 提交的揭露文件,以完整了解相關風險。
DexCom today reported a net loss of $11.1 million for the fourth quarter of 2006 and a loss of $46.6 million for the full fiscal year of 2006 compared to a net loss of $12.1 million and $30.9 million respectively for the fourth quarter and full years ending December 2005. We also reported today a net loss per share of $0.39 per share for the fourth quarter of 2006 compared to a loss of $0.48 per share for the fourth quarter of 2005. For the full year ending December 2006, we recorded a net loss per share of $1.71 compared to a loss of $1.63 per share for fiscal 2005.
DexCom 今日公布,2006 年第四季淨損為 1,110 萬美元,2006 會計年度全年淨損為 4,660 萬美元;相較之下,2005 年 12 月止之第四季與全年分別為淨損 1,210 萬美元與 3,090 萬美元。我們今日亦公布,2006 年第四季每股淨損為 0.39 美元,相較 2005 年第四季每股淨損 0.48 美元。就截至 2006 年 12 月的全年而言,我們每股淨損為 1.71 美元,相較 2005 會計年度每股淨損 1.63 美元。
Today, we reported revenue of $835,000 for the fourth quarter of 2006 and $2.2 million for the fiscal year, full fiscal year after launching our STS in late March of 2006. As we disclosed at Investor Conference in January, we added approximately 840 new customers during the fourth quarter in spite of being constrained by product supply for much of the quarter. So, in spite of relatively stable new customer acquisition during the fourth quarter, we're still able to grow center revenues 23% sequentially while ending 2006 on backorder.
今日我們公布,2006 年第四季營收為 83.5 萬美元,全年營收為 220 萬美元;此為我們於 2006 年 3 月下旬推出 STS 之後的完整會計年度營收。如同我們在 1 月投資人會議中所揭露,儘管本季大部分時間受限於產品供應,我們在第四季仍新增約 840 位新客戶。因此,儘管第四季新客戶取得相對穩定,我們仍能使中心(center)營收較前一季成長 23%,並在 2006 年底仍處於缺貨待交(backorder)狀態。
Gross margin loss of $2.6 million for the fourth quarter of 2006 compared sequentially to a gross margin loss of $2.5 million for the third quarter of 2006. For the full year, our loss at the gross margin line was a $8.8 million. There is no meaningful comparison to 2005 as these costs were included in research and development while we were still in the development stage.
2006 年第四季毛利為虧損 260 萬美元,與 2006 年第三季毛利虧損 250 萬美元相比屬於連續比較。全年而言,我們在毛利項下的虧損為 880 萬美元。由於 2005 年時這些成本仍包含在研發費用中(當時我們仍處於開發階段),因此與 2005 年並無具意義的比較基礎。
As mentioned previously, the majority of our cost of goods sold are fixed in nature and will begin to be absorbed into inventory at a higher rate as we grow our sales and production. Adding to the higher volume based absorption going forward will be efficiency improvements in our production areas and Andy will discuss those more fully during his review.
如先前所提,我們銷貨成本中的大部分屬固定性質;隨著銷售與產量成長,這些固定成本將以更高的比率被吸收進存貨。未來除因產量提升帶來更高的吸收外,我們在生產區域也將進行效率改善;Andy 會在他的回顧中更完整地說明。
Research and development expense, including stock based compensation decreased $7 million to $3.9 million for the fourth quarter of 2006 compared to $10.9 million for the fourth quarter of 2005. Excluding the $6.9 million in manufacturing costs that were included in R&D in the fourth quarter of 2005, research and development costs actually declined $160,000 from the fourth quarter of 2005 to the fourth quarter of 2006.
研發費用(含以股票為基礎之酬勞)在 2006 年第四季較 2005 年第四季由 1,090 萬美元下降 700 萬美元至 390 萬美元。若排除 2005 年第四季納入研發費用中的 690 萬美元製造成本,研發成本實際上從 2005 年第四季到 2006 年第四季僅下降 16 萬美元。
Likewise, a $3.9 million in R&D spending for the fourth quarter of 2006 also declined sequentially by approximately $700,000 compared to the $4.6 million of spending in the third quarter of 2006. The sequential decline was primarily due to the reversal of the 2006 bonus accrual in the fourth quarter, as no bonus was paid during 2006 for performance. As noted previously, we are endeavoring to hold our R&D energy and expenses flat while continuing to invest in new product development and our sales efforts and we are pleased at the progress we have made to date in those controls.
同樣地,2006 年第四季研發支出 390 萬美元,較 2006 年第三季的 460 萬美元亦連續下降約 70 萬美元。此一連續下降主要是因第四季沖回 2006 年獎金應計數,因 2006 年未因績效而發放獎金。如先前所述,我們致力於在持續投資新產品開發與銷售推動的同時,將研發投入與費用維持持平;我們對迄今在這些控管上所取得的進展感到滿意。
Selling, general, and administrative expense including stock based compensation increased $3.6 million to $5.3 million for the fourth quarter of 2006 compared to $1.7 million for the fourth quarter of 2005. The increase is primarily due to $3 million in higher sales and marketing costs and $666,000 in higher general and administrative expenses as we continue to launch our STS system in the United States.
銷售、一般及行政費用(含以股票為基礎之酬勞)在 2006 年第四季較 2005 年第四季由 170 萬美元增加 360 萬美元至 530 萬美元。增加主要來自銷售與行銷成本增加 300 萬美元,以及一般與行政費用增加 66.6 萬美元,因我們持續在美國推出 STS 系統。
Driving the higher spending was $2.6 million in higher compensation cost, primarily in the sales area, $329,000 for increased promotions and advertising, and $317,000 in higher auditing and Sarbanes-Oxley compliance expenses. For the full 2006 fiscal year, our SG&A spending reached $21.1 million or an increase of $15.4 million compared to our spending of $5.7 million during 2005. The majority of the increase was related to the institution of our sales force and our marketing capabilities, although public company expenses also increased related to Sarbanes-Oxley compliance and the fact that 2006 had four full quarters of public company expenses compared to just three quarters of being public in 2005.
推動支出上升的因素包括:薪酬成本增加 260 萬美元(主要在銷售部門)、促銷與廣告增加 32.9 萬美元,以及稽核與《沙賓法案》(Sarbanes-Oxley)合規費用增加 31.7 萬美元。就 2006 會計年度全年而言,我們的 SG&A 支出達 2,110 萬美元,較 2005 年的 570 萬美元增加 1,540 萬美元。增加的大部分與建立我們的銷售團隊與行銷能力有關;此外,因《沙賓法案》合規以及 2006 年包含四個完整季度的上市公司費用(相較 2005 年僅有三個季度為上市公司)而使上市公司相關費用亦有所增加。
Our net interest income and expense increased $147,000 to $684,000 for the fourth quarter of 2006 compared to $537,000 for the fourth quarter of 2005. For the full year, interest income increased $1.1 million to $2.7 million for fiscal 2006 compared to $1.7 million for 2005. The increase here was due to higher investable balances as well as moderately higher interest rates.
2006 年第四季淨利息收入(及費用)較 2005 年第四季由 53.7 萬美元增加 14.7 萬美元至 68.4 萬美元。全年而言,2006 會計年度利息收入較 2005 年由 170 萬美元增加 110 萬美元至 270 萬美元。此處增加係因可投資餘額較高,以及利率溫和上升所致。
We ended the year with a strong balance sheet. As of December 31, we had working capital of $52 million, which includes $54.5 million in cash and cash equivalents and our marketable securities. During 2006, we accessed $3 million on our bankline to cover $3.4 million in equipment and leasehold improvements expenses and we will start repaying that loan on a 30-month amortized basis starting in April.
我們在年底擁有強健的資產負債表。截至 12 月 31 日,我們的營運資金為 5,200 萬美元,其中包含 5,450 萬美元的現金及約當現金與可供出售之有價證券。2006 年期間,我們自銀行授信額度動用 300 萬美元,以支應 340 萬美元的設備與租賃改良支出;我們將自 4 月起以 30 個月攤還方式開始償還該筆貸款。
Net cash used in operating activities increased $21 million to $43.6 million for fiscal 2006 compared to $22.6 million for fiscal 2005. The increase in cash used in operations was primarily due to the increase in our net loss as well as lower accounts payable and accrued liabilities and $1.4 million in our initial inventories. Net cash provided by financing activities increased $473,000 to $51.2 million for the 12 months ended December 31, 2006 compared to approximately $51 million for the same period in 2005. The increase was primarily due to approximately $1 million in proceeds from exercise of stock options and the proceeds from our 2006 follow-on offering and our bankline draws in 2006 approximating $50 million were about the same as our 2005 IPO proceeds.
2006 會計年度營業活動使用之淨現金較 2005 會計年度由 2,260 萬美元增加 2,100 萬美元至 4,360 萬美元。營運用現金增加主要係因淨損擴大,以及應付帳款與應計負債降低,並包含 140 萬美元的初始存貨。就截至 2006 年 12 月 31 日的 12 個月而言,籌資活動提供之淨現金較 2005 年同期約 5,100 萬美元增加 47.3 萬美元至 5,120 萬美元。增加主要來自約 100 萬美元的員工行使股票選擇權所得款項,以及我們 2006 年後續發行(follow-on offering)的募集款與 2006 年銀行授信動用款;2006 年合計約 5,000 萬美元,與 2005 年 IPO 募集款大致相當。
With that, I'll just turn it back now to Andy Rasdal, our CEO, for his comments.
那麼,我現在把時間交還給我們的執行長 Andy Rasdal,請他發表評論。
Andy Rasdal - CEO
Andy Rasdal - CEO
Thanks, Steve. I'd like to provide a little color to the quarter that we're currently in since our last update at Investor Conference in early January. To begin, we'll talk about some of the key commercialization issues.
謝謝你,Steve。自從我們在一月初的投資人會議上次更新以來,我想就我們目前所在的這一季提供一些補充說明。首先,我們將談談一些關鍵的商業化議題。
First, with manufacturing. We've made a continued and a substantial progress in our manufacturing operations to both improve quality and produce higher levels of product availability as well as reducing unit costs including increasing yields and decreasing variability in our manufacturing operations. Overall sensor yields have improved over 75% from December to February, and product supply today is not currently limiting our sales efforts.
首先是製造方面。我們在製造營運上持續且大幅取得進展,既提升品質、提高產品供應量,同時也降低單位成本,包括提高良率並降低製造作業中的變異性。整體感測器良率從12月到2月提升了超過75%,而目前產品供應並未限制我們的銷售推進。
Beyond just the yield performance, we've continued to make progress in automating key manufacturing processes to increase throughput, further reduce costs and improve future scalability. We have received approval from the FDA for two manufacturing changes to automate two of our key three processes and expect to file on a third one shortly. These three key processes relate to preparing the initial sensor wire, applying the membrane system and final performance testing.
除了良率表現之外,我們也持續推進關鍵製造流程的自動化,以提高產能、進一步降低成本並改善未來的可擴充性。我們已獲得 FDA 核准兩項製造變更,用以自動化我們三項關鍵流程中的兩項,並預期不久將就第三項提出申報。這三項關鍵流程分別與初始感測器導線的製備、膜系統的塗佈,以及最終效能測試相關。
We aim to implement these improvements carefully over the next few months. When successfully implemented, we believe these changes will create very substantial improvements in throughput volume, require fewer people, and further reduce our manufacturing unit costs.
我們的目標是在未來幾個月內謹慎地導入這些改善。若能成功導入,我們相信這些變更將大幅提升產出吞吐量、需要更少人力,並進一步降低我們的製造單位成本。
Product performance and quality as measured by complaint rate data from the field continues to be improved since the fourth quarter, while at the same time, manufacturing volumes have increased and we are pleased with that, obviously, improvement and product performance as we have scaled further. Qualitative reports from our field personnel additionally about product performance are also very encouraging at this time.
以現場客訴率數據衡量的產品效能與品質,自第四季以來持續改善;同時,製造量也已增加,我們對於在進一步擴產過程中仍能看到這些改善與產品表現感到非常滿意。此外,我們現場人員對產品表現的質性回饋目前也相當令人鼓舞。
During the month of January, the FDA conducted their post- PMA approval audit of our facilities operations in quality systems. Additionally, they also inspected aspects of our new larger manufacturing facilities for future expansion. The inspection was a standard post-approval audit as well as for our new facilities and not for cause or in response to any issues. The audit, though, was quite thorough and intensive with the two inspectors spending nearly eight days at our facilities. Based on the results and findings of the audit, we believe that we are in compliance with requirements for medical device manufacture and we are told at the close of that meeting there would be no action indicated.
在一月份,FDA 針對我們的設施營運與品質系統進行了 PMA 核准後稽核。此外,他們也檢查了我們新的、更大型製造設施的部分面向,以因應未來擴產。此次檢查屬於標準的核准後稽核以及新設施查核,並非因任何原因或回應任何問題而來。不過,稽核相當全面且密集,兩位稽核員在我們設施內待了將近八天。根據稽核結果與發現,我們相信我們符合醫療器材製造的相關要求,且在會議結束時我們被告知不會有任何後續處置。
We did receive some minor observations during the inspections as we did with our first one back prior to our PMA approval. Although we have no requirement to formally respond to any of these observations, we believe as is best practice, we will voluntarily close out all of these observations and provide formal written documentation to the FDA shortly on those observations.
在檢查期間我們確實收到一些輕微的觀察事項,就如同在我們首次、也就是在 PMA 核准前的那次檢查一樣。雖然我們沒有義務就這些觀察事項正式回覆,但我們認為依最佳實務做法,我們將自願結案所有觀察事項,並在近期向 FDA 提交相關的正式書面文件。
Today, just today, we also received approval from the FDA for our expanded component manufacturing in our new larger facility, which is important for expanded capacity going forward into the future.
今天,就在今天,我們也收到 FDA 對於我們在新的更大型設施中擴增零組件製造的核准,這對於未來擴充產能非常重要。
On the demand and revenue side of things, our manufacturing improvements and increased volumes enabled us to fill the existing backorder during January. We've now been out of backorder for several weeks in a row and have sensor inventory on the shelf today. As a result, approximately mid-January, begin to provide product for our field force to begin again driving new customer adoptions.
在需求與營收方面,我們的製造改善與產量提升使我們得以在一月份消化既有的積壓訂單。我們已連續數週不再有缺貨積壓,目前也有感測器庫存可供出貨。因此,大約在一月中旬,我們開始能夠提供產品給前線銷售團隊,重新推動新客戶採用。
Thus far in Q1, new customer additions and revenue rates are roughly the same as Q4 2006, but after not being able to readily fulfill customer order and sales rep demand in the third and fourth quarter of 2006 due to supply limitations, and the sensor performance issues we reported customers experienced during those quarters, we believe there's some lag in restarting the channel for new patients and some time is needed to re-establish credibility with prescribing centers.
截至目前第一季,新客戶增加數與營收速度大致與 2006 年第四季相同;但由於 2006 年第三與第四季受供應限制影響,我們無法即時滿足客戶訂單與業務代表需求,加上我們先前回報客戶在那些季度所經歷的感測器效能問題,我們認為在重新啟動新病患導入通路上存在一些滯後,且需要時間重新建立處方中心的信任。
We're focusing our efforts on creating positive experience [with] those centers that can make them strong advocates for continuous glucose monitoring DexCom so that they will felt comfortable endorsing and supplying to increasing numbers of new patients. Further, we hear some reports now that some customers may be waiting for second generation seven-day product. Although too early in dynamic to provide any firm estimates, if new patient rates don't accelerate as a result of our improvement efforts, we would expect Q1 revenue to be comparable to Q3, Q4 of 2006.
我們正把重點放在為這些中心創造正面的使用體驗,使其成為 DexCom 連續血糖監測的強力倡議者,讓他們能夠放心地推薦並供應給更多新病患。此外,我們也聽到一些回報指出,部分客戶可能在等待第二代七天產品。雖然目前仍太早,無法就此動態提供任何明確估計,但若新病患導入速度未因我們的改善努力而加速,我們預期第一季營收將與 2006 年第三、第四季相當。
Last week, we had the entire field force together in San Diego for the week primarily related to product training. I was generally impressed by their high level of enthusiasm, commitment, and persistence in [empiring] this continuous glucose monitoring category. All of us, and myself included had a fair amount of interaction with them and it was encouraging and I think invigorating because in them I saw the true belief and passion that CGM represents, a major step forward in diabetes management and they are the people in contact with physicians and patients every day. They are almost evangelical about driving this technology for the patient and health-care professionals. So I remain optimistic about the potential impact this motivated and capable group in the field will now make that they have -- now that they have adequate product supply and if and when improved, the second generation seven-day STS.
上週,我們讓整個前線團隊齊聚聖地牙哥一週,主要進行產品訓練。我整體上對他們在推動這個連續血糖監測類別方面所展現的高度熱忱、投入與堅持印象深刻。我們所有人(包括我自己)都與他們有相當多的互動,這令人鼓舞,也讓人振奮,因為我在他們身上看到了對 CGM 的真正信念與熱情;CGM 代表糖尿病管理的一大進步,而他們是每天與醫師與病患接觸的人。他們幾乎以傳教般的熱忱在向病患與醫療專業人員推動這項技術。因此,我仍對這支充滿動力且能力出眾的前線團隊未來所能帶來的影響保持樂觀——現在他們已有充足的產品供應,並且在改良後,若及當第二代七天 STS 推出。
On the reimbursement front, we submitted an application for a [hixpix] code in January with strong supporting evidence. Medtronic also supported a [hixpix] application again as well. We would expect a preliminary decision on the [hixpix] application sometime towards the end of Q1 or beginning of Q2 with a final determination late fall.
在給付(reimbursement)方面,我們在一月份提交了 [hixpix] 代碼申請,並附上強而有力的支持證據。Medtronic 也再次支持一項 [hixpix] 申請。我們預期 [hixpix] 申請的初步決定將在第一季末或第二季初左右出爐,最終裁定則在秋末。
We are aware that the JDR reimbursement trial, the randomized clinical trial there has begun enrollment and we are providing product for that enrollment at this time. We continue to receive unsolicited ports from new patients and physicians, a favorable coverage decision, and our dedicated reimbursement organization is working to most appropriately build upon these experiences to create wider spread reimbursement and clarity going forward.
我們了解到 JDR 給付試驗(隨機臨床試驗)已開始收案,我們目前正為該收案提供產品。我們也持續收到來自新病患與醫師的非主動回報,內容包括有利的給付覆蓋決定;我們專責的給付團隊正努力以最適當的方式在這些經驗基礎上持續推進,以在未來建立更廣泛的給付覆蓋與更清晰的規範。
On our seven-day second generation product, we are currently engaged in more active dialogue with the FDA on that product. Just recently, the FDA has requested and we have provided additional reformatted tables of data we had previously submitted. We view these interactions as positive and moving forward towards an FDA decision regarding approvability of our seven-day CGM system and although we can't predict the ultimate decision or timing for a decision by the FDA, it would seem that we're still on track for a decision in Q2 of 2007.
關於我們的第二代七天產品,我們目前正就該產品與 FDA 進行更積極的對話。最近,FDA 要求我們提供先前已提交資料的額外重新格式化數據表,我們也已提供。我們將這些互動視為正向訊號,並正朝向 FDA 對我們七天 CGM 系統可核准性的決定邁進。雖然我們無法預測 FDA 最終決定或決定時點,但看起來我們仍有望在 2007 年第二季取得決定。
As we sit back and look and evaluate the status of the category, it becomes more clear every day that DexCom is a pioneer in the CGM category and changing the standard of care takes time and leadership commitment. Our daily experiences continue to reinforce the patients and health- care professionals and make a commitment to using this product for a period of time, irrespective of first generation performance issues, obtaining the best levels of glucose control ever. We continue to get reports about best ever improvements in A1-C levels from patients and physicians who have been using the product for several months at a time and in spending time with our field force last week, that just becomes reiterated.
當我們回頭檢視並評估這個類別的狀態時,每一天都更清楚地看到 DexCom 是 CGM 類別的先驅,而改變照護標準需要時間與領導層的承諾。我們的日常經驗持續強化一點:病患與醫療專業人員只要承諾使用本產品一段時間,即使不考慮第一代的效能問題,也能達到前所未有的最佳血糖控制水準。我們持續收到病患與醫師回報,指出在連續使用數個月後,A1-C 指標出現「史上最佳」的改善;而我上週與前線團隊相處時,這點也再次被印證。
And so we continue to believe that we have something which is both important and meaningful. We believe as much as ever that CGM will increasingly play an important role in the future of diabetes and will be a growing and profitable business.
因此,我們仍然相信我們擁有一項既重要又具意義的產品。我們比以往任何時候都更相信,CGM 將在糖尿病未來照護中扮演日益重要的角色,並將成為一項成長且具獲利性的業務。
On the in-hospital opportunity and application of this technology, we spoke a little bit at a conference in early January and I would like to cover some of that same material, but also provide a little bit further clarity and update. We continue to believe that the in-hospital application of continuous glucose monitoring is a very important and large opportunity. Published data continues to provide compelling evidence that the intensive glucose control and insulin therapy in post-surgery intensive care significantly reduces mortality and morbidity, and so this isn't dealing with complications occurring tens of years later, but with acute and immediate clinical consequences of people post-surgery.
關於院內(in-hospital)機會以及這項技術的應用,我們在一月初的一場會議上曾稍作說明;我想在此涵蓋部分相同內容,同時也提供更進一步的釐清與最新進展。我們仍然相信,連續血糖監測在院內的應用是一個非常重要且龐大的機會。已發表的數據持續提供有力證據顯示,在術後加護病房中進行嚴格的血糖控制與胰島素治療,能顯著降低死亡率與罹病率;因此,這並非在處理數十年後才出現的併發症,而是與術後病患急性且立即的臨床後果相關。
Intensive glucose control and insulin therapy regimes are starting to be addressed and evaluated by accreditation bodies for these hospitals. From a citing standpoint, there are an estimated 100,000 critical care beds in the U.S. and we believe approximately 25% of U.S. hospitals have begun implementing intensive glucose control and insulin therapy, often involving 12 to 24 fingersticks per day per patient.
各認證機構已開始針對這些醫院的嚴格血糖控制與胰島素治療方案進行關注與評估。就引用數據而言,美國估計約有100,000張重症照護病床,我們認為約25%的美國醫院已開始導入嚴格血糖控制與胰島素治療,且往往每位病患每天需要進行12到24次指尖採血測試。
It is estimated that about 25% of patients admitted to the hospital have diabetes. There are approximately 450,000 cardiovascular surgeries per year and it's estimated approximately 30% of these patients have diabetes. For those hospitals already practicing intensive glucose control, CGM could significantly reduce the workload and the cost while improving the quality of care. Published studies have estimated the cost of these bedside fingerstick tests at $3 to $5 per test.
據估計,約有25%的住院病患患有糖尿病。每年約有450,000例心血管手術,估計其中約30%的病患患有糖尿病。對於已在實施嚴格血糖控制的醫院而言,CGM可在提升照護品質的同時,大幅降低工作量與成本。已發表研究估計,這些床邊指尖採血測試的成本為每次3至5美元。
So, as we said, we focused on developing a product addressing this critical care opportunity. The product is IV-based with simple insertion and used consistent with the practices and techniques in the critical care areas. Design is simple and requires minimal hardware capital investment. The product, much like our current ambulatory system, provides current glucose value, trended glucose data and, of course, high and low alerts.
因此,如同我們所說,我們專注於開發一項可因應此重症照護機會的產品。該產品以靜脈(IV)為基礎,置入簡便,且使用方式與重症照護區域的既有作業與技術一致。設計簡單,所需硬體資本投入極低。該產品與我們目前的攜帶式系統類似,可提供即時血糖值、血糖趨勢資料,當然也包含高、低血糖警示。
In bench and animal testing, as we previously said, the product has been highly accurate and stable. In early January, we said we hoped to conduct initial human use of the product in the first quarter of 2007. We have now completed our first human studies using the device with very satisfying results. In the latest small initial study, the system was more accurate and reliable than a traditional blood glucose meter when both were compared to YSI laboratory reference standard.
在台架與動物測試中,如我們先前所述,該產品展現出高度準確且穩定的表現。今年一月初,我們表示希望在2007年第一季進行該產品的首次人體使用。我們現已完成使用該裝置的首批人體研究,結果令人非常滿意。在最近一項小型初步研究中,當系統與傳統血糖機皆與YSI實驗室參考標準進行比較時,本系統的準確性與可靠性均優於傳統血糖機。
We're pleased with the speed and the progress of the project and intending to enroll additional patients in a series of feasibility trial to rapidly evolve the technology into a commercial product platform for the continuous monitoring of glucose in the critical care areas of the hospital.
我們對專案的速度與進展感到滿意,並計畫在一系列可行性試驗中納入更多病患,以快速將此技術演進為商業化產品平台,用於醫院重症照護區域的連續血糖監測。
Although it's still too early to accurately predict a commercialization timeline, we're working to find the best clinical and regulatory path for the product and we certainly hope to have more to say, both on our clinical results as well as the timing and the path at our next quarterly call.
雖然目前仍過早,尚無法精準預測商業化時程,但我們正努力為該產品尋找最佳的臨床與法規路徑;我們也希望在下一次季度電話會議上,能就臨床結果,以及時程與推進路徑提供更多說明。
We are determined to ensure that DexCom has the staying power to drive development of the continuous glucose monitoring market and to meaningfully participate as it matures into a larger business. We desire to ensure that the time and resources are available as to implement a well proven strategy we believe to drive a new treatment category.
我們決心確保DexCom具備長期競爭力,以推動連續血糖監測市場的發展,並在其成熟為更大型的業務之際,能夠實質參與其中。我們希望確保有足夠的時間與資源,以落實一套經充分驗證、我們相信可推動新治療類別的策略。
First, we intend to continue developing next generation products with a performance that appeals to larger segments of the target population, gets away with the first generation issues that are always present and drives towards easier, more convenient, more reliable, more usable, and more cost-effective products.
第一,我們打算持續開發下一代產品,使其性能能吸引更大範圍的目標族群,擺脫第一代產品必然存在的問題,並朝向更容易、更便利、更可靠、更好用且更具成本效益的產品邁進。
Second, we intend to create the experience and continue to publish evidence for health-care professionals to widely accept and adopt continuous glucose monitoring as a primary means for diabetes management; and third, to drive increase to clear reimbursement in this market.
第二,我們將打造相關使用經驗並持續發表證據,讓醫療專業人員能廣泛接受並採用連續血糖監測作為糖尿病管理的主要方式;第三,推動本市場取得更明確的給付(reimbursement)。
Going forward, we plan to provide the required cash resources from one or more of the following -- a loan or in combination. We have the potential to make business adjustments to place spending more in line with revenue performance as we obtain that information; additional financing and business partnerships. And although we cannot comment on the specifics of any potential business adjustment to reduce spending if revenue does not accelerate, we have previously demonstrated our ability to appropriately focus resources on activities that enhance value for all of our key constituencies.
展望未來,我們計畫透過下列一項或多項方式(例如貸款或其組合)提供所需的現金資源。我們也可能進行業務調整,使支出更貼近營收表現(在取得相關資訊後);以及尋求額外融資與業務合作夥伴關係。雖然我們無法就任何潛在的業務調整細節(若營收未加速而需降低支出)發表評論,但我們過去已展現出能適當聚焦資源於可為所有關鍵利害關係人提升價值之活動的能力。
We believe our in-hospital continuous glucose monitoring product is an outstanding opportunity for partnership. We're pleased with the progress of the project and would expect to more aggressively explore a partnership with appropriate companies to most effectively address this important market in the future. Further, in the first year of commercializing the STS now, we've learned a great deal about the potential for CGM to be integrated with other diabetes management products to improve the convenience and effectiveness of diabetes managements. We would expect to more aggressively pursue such partnerships that will provide for mutual beneficial integration.
我們認為院內連續血糖監測產品是極佳的合作夥伴機會。我們對專案進展感到滿意,並預期未來將更積極與合適的公司探討合作,以最有效地切入這個重要市場。此外,在目前STS商業化的第一年,我們已學到許多關於CGM與其他糖尿病管理產品整合的潛力,這可提升糖尿病管理的便利性與有效性。我們預期將更積極推動此類合作,以達成互利的整合。
So I think just in conclusion, finally, again, as we continue to gain experience here, we believe as much as ever that the continuous glucose monitoring will play an increasingly important role in the future of diabetes as real meaning and impact to people with diabetes and will be a growing and profitable business.
因此我想在結語中再次強調,隨著我們持續累積經驗,我們比以往任何時候都更相信,連續血糖監測將在糖尿病的未來扮演日益重要的角色,對糖尿病患者帶來真正的意義與影響,並將成為一項成長且具獲利性的業務。
And so with that, we could open up to a few questions.
那麼,接下來我們可以開放幾個問題。
Operator
Operator
(OPERATOR INSTRUCTIONS). Thom Gunderson, Piper Jaffray.
(接線員指示)。Thom Gunderson,Piper Jaffray。
Thom Gunderson - Analyst
Thom Gunderson - Analyst
Three questions really, Andy. Number one is after three quarters now of watching patient usage and looking at reorder rates, are you getting a better sense of how that's trending? Did it stabilize, are people using sensors longer, shorter, et cetera?
Andy,我其實有三個問題。第一,在觀察病患使用情況並查看再訂購率已經三個季度之後,你們是否對其趨勢有更清楚的掌握?是否已趨於穩定?人們使用感測器的時間是變長、變短,等等?
Andy Rasdal - CEO
Andy Rasdal - CEO
I think, first, the only data I think we can probably cite right now is Steve's fourth quarter data that sensors grew more rapidly than new patients. And I think that's encouraging. The trouble is it's still hard to use data to determine that, when we're really just, although we're pleased with the manufacturing, been out of backorder for several weeks, the fact that we filled so much of that backorder in January and people play the normal thing of placing orders because they know we're in backorder to try to get more product sooner, and then we deliver late, we set up interference as a normal reorder cycle. But right now, it's just hard to get any clarity internally on what those usage rate, let alone provide any accurate guidance externally.
我想,首先,我們目前大概唯一能引用的數據是Steve的第四季數據:感測器的成長速度快於新病患的成長。我認為這是令人鼓舞的。問題在於,仍然很難用數據做出判斷;雖然我們對製造狀況感到滿意,且已經脫離缺貨狀態好幾週,但由於我們在一月消化了大量積欠訂單,而人們也會出於常態行為——因為知道我們缺貨而先下單以期更快拿到更多產品——結果我們延後交付,這就會干擾正常的再訂購週期。因此目前我們內部很難釐清實際使用率,更不用說對外提供任何準確指引。
Thom Gunderson - Analyst
Thom Gunderson - Analyst
And then, second, Andy, you mentioned that you had the whole sales force in last week. You remind us what those - - how many people showed up for that? How many of them were actually sales responsible for revenue in their territories? And how many of them have been there more than six months?
第二個問題,Andy,你提到上週把整個銷售團隊都召回來了。你能提醒我們——那次有多少人出席?其中有多少人是對其負責區域的營收負責的銷售人員?又有多少人在公司任職超過六個月?
Andy Rasdal - CEO
Andy Rasdal - CEO
Well, they all showed up and I'm pleased to say that based on my observation, they showed up and they were all awake and paying attention. And as we said previously, we have just over 40 people with territory responsibility comprised of both education specialists and sales reps. All of them, despite some delineation roles have clear revenue in new customer acquisition targets and performance criteria. That's been stable now for some time and I think again, I'm very impressed with the level of morale and nearly all of those have been, and I can't quote the exact number, but nearly all of those have been here for more than six months now.
嗯,他們全都出席了;我也很高興地說,依我觀察,他們都到場了,而且都清醒並專心聽講。如我們先前所說,我們有略多於40位負責區域的同仁,包含教育專員與業務代表。儘管角色分工有所區隔,但他們每一位都有明確的營收、新客戶開發目標與績效標準。這樣的架構已穩定一段時間;我也再次強調,我對士氣水準印象非常深刻,而且幾乎所有人——我無法報出確切數字——幾乎都已在這裡超過六個月。
Thom Gunderson - Analyst
Thom Gunderson - Analyst
And then last question is on reimbursement, you talked about [hixpix], you talked about JDRF. Can you give us any granularity, any color on individual private pairs that are beginning to see the light or where you're making more progress?
最後一個問題是關於給付。你談到了[hixpix],也談到了JDRF。你能否提供更細的資訊、更多背景,例如哪些個別的民間保險支付方開始看見價值,或你們在哪些地方取得更多進展?
Andy Rasdal - CEO
Andy Rasdal - CEO
Well, I think we -- I'm so used to hearing what people don't like and what's wrong, of course, but the anecdotal reports that we just continue to get in relate to successes in individual patients and physicians obtaining reimbursements. Again, today, they make a decision generally to purchase it and then seek reimbursement after. In some cases, when initial reimbursement is denied, subsequent appeal with a letter from the physician seems to work. I don't -- as we released previously, just about every national name at least a local level has made a one- off decision to do that. We're in the process of trying to capture, harness that, [and] figure which pieces are localized and then have the ability to try to begin to drive local policy, but we don't have anything material or concrete that we could point to as to whether there's been a firm decision or a denial of a decision related to a policy.
嗯,我想我們——我太習慣聽到人們不喜歡什麼、哪裡有問題了,當然——但我們持續收到的軼聞回報,主要是關於個別病患與醫師成功取得給付的案例。再次強調,目前通常是先決定購買,之後再去申請給付。在某些情況下,若初次給付遭拒,後續提出申訴並附上醫師來函似乎就能奏效。我不——如我們先前發布所述,幾乎每一家全國性知名保險公司至少在地方層級都曾做過一次性的核准決定。我們正嘗試蒐集並整合這些案例,[並]釐清哪些因素屬於地方性,進而具備推動地方政策的能力;但目前我們沒有任何重大或具體的內容可指出,是否已就某項政策做出明確決定,或是否存在與政策相關的否決決定。
Operator
Operator
Sara Michelmore, Cowen and Company.
Sara Michelmore,Cowen and Company。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Andy, as you're heading into this kind of Q2 decision or response, I should say from the FDA on the 70 sensor, I'm just wondering in terms of your communications with them, if you feel like they are holding the products to a higher standard than you saw the first time around? I asked that just in response to some of the feedback we've had from Abbott and through their experience and it may just be company specific, but if you could comment on that.
Andy,當你們正要進入這種第二季(Q2)關於 FDA 對 70 感測器的決定或回覆(我應該說)的階段,我想請教,就你們與他們的溝通而言,你是否覺得他們對產品的要求標準,比你們第一次經歷時更高?我之所以這麼問,是因為我們從 Abbott 那邊以及他們的經驗中收到一些回饋;也許只是公司個別情況,但如果你能對此評論一下就太好了。
And secondarily, with regard to the facility inspection, I'm wondering if that was actually prompted by the review of the seven-day sensor, if that was an entirely separate issue.
其次,關於工廠稽查(facility inspection),我想知道那是否其實是因為審查七天感測器而被觸發的,還是那完全是另一個獨立的事項。
Andy Rasdal - CEO
Andy Rasdal - CEO
Let me deal with the last one first. To our knowledge, and we were told this was just a standard required post-PMA approval inspection. Additionally, because we had filed for expansion of our manufacturing to some new facilities, we asked them to do that during the same visit, and whereas it could have been somehow initiated, propagated, related to seven-day, I can't make any comment as to whether that was true or not. We certainly weren't informed of that piece.
我先回答最後一個問題。就我們所知,而且我們被告知這只是 PMA 核准後的標準、必要稽查。此外,因為我們已申請將製造擴展到一些新設施,我們也請他們在同一次訪視中一併進行;至於它是否可能以某種方式被啟動、被推動、或與七天產品相關,我無法評論那是否屬實。我們當然沒有被告知那一部分。
Relative to the communications with the FDA or what we can divine from that, I think that the best way to categorize the review is consistent with the review of the original PMA. Whether it's being held to a higher standard or not, the good news is if you've seen the published data, this is a very strong data set in and of its own and certainly compared to our first generation product. The data that we've demonstrated is very, very strong. And so, though, like I said, we can't predict what the ultimate decision or timing is, based upon the kind of interactions and responses we have right now. We believe that we are moving forward towards a decision on the expected timeline of sometime in early Q2.
至於與 FDA 的溝通,或我們能從中推斷出的內容,我認為最好的描述方式是:這次審查與原始 PMA 的審查一致。至於是否被要求更高標準,好消息是,如果你看過已發表的數據,這本身就是一組非常強而有力的資料集,且當然相較於我們第一代產品更是如此。我們所展示的數據非常、非常強勁。因此,雖然如我所說,我們無法預測最終決定或時程,但基於目前我們的互動與回覆情況,我們相信正朝著預期時程推進,也就是在第二季初的某個時間點做出決定。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
And then in terms of the manufacturing challenges that you've had, it seems like there's been a kind of a host of things that you've been up against; everything from yield to supply issue to need to automate to variability. If you could, sort of in rank order, talk about what's been the most difficult to overcome and just give us a sense of where you are on some of the most notable issues.
另外,就你們遇到的製造挑戰而言,看起來你們面臨了一連串問題;從良率到供應問題、到需要自動化、到變異性。如果可以的話,能否按重要性排序談談哪些最難克服,並讓我們了解一下你們在一些最顯著問題上的進展到哪裡了。
Andy Rasdal - CEO
Andy Rasdal - CEO
I don't know that any of them are particularly more difficult than the other. I think we've always characterized these as first generation, first product initial scaling, early commercialization types of issues. We did get through the regulatory process fairly rapidly and the evolution of moving from a commercial company to a -- from a technology company to a commercial company occurred pretty rapidly in what I think is certainly a difficult and challenging product category for a number of people to do it, and so really it's been time. It's been tracking and diagnosing issues and failures and then, finding real causes; benchmarking the status and then implementing standard good old manufacturing engineering for process [improvement] that drives it (indiscernible). But there's nothing, any one thing that's major. These are just -- I think the things that we would expect and I think based on where we are today, and the fact that products supply is no longer limiting our efforts here today, and that product performance is measured by the best data we can get, appears where we would like it to be, and we've been able to make progress and have two of three key processes receive approval for automation is very encouraging going forward from a manufacturing -- and from a scale standpoint, not that there aren't bumps and that isn't hard, but there's no one specific thing that is necessarily a big issue -- (multiple speakers)
我不確定其中任何一項是否特別比其他更難。我想我們一直把這些描述為第一代、第一個產品在初期擴產、早期商業化階段會遇到的問題。我們確實相當快速地走完法規流程,而從技術公司轉型為商業公司——從一家技術公司到一家商業公司——的演進也發生得很快;我認為這在一個對許多人而言都很困難、很具挑戰性的產品類別中尤其如此,所以真正需要的是時間。需要追蹤並診斷問題與失敗,然後找出真正原因;對現況做基準評估,接著導入傳統、扎實的製造工程流程(改善)來推動(聽不清楚)。但沒有任何單一重大事項。這些只是——我想是我們預期會發生的事。而且就我們今天的狀況來看,產品供應已不再限制我們目前的努力;產品表現以我們能取得的最佳數據衡量,看起來也達到我們希望的水準;此外,我們也已能讓三個關鍵製程中的兩個取得自動化核准,這對未來在製造與規模化角度而言非常令人鼓舞;並不是說不會有顛簸、也不是說不難,但沒有任何一個特定事項必然是很大的問題——(多位講者)
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Now in terms of -- you did have out of the box failures and I'm just wondering in terms of your ability to sort of pick up bad product at sort of the end of the manufacturing procedure. Have you been able to put any systems or QAQCs, things in place there to help you kind of catch the quality of the product before it heads out the door?
那麼就——你們確實有開箱即故障(out of the box failures)的情況,我想知道在製造流程末端,你們是否有能力把不良品挑出來。你們是否已建立任何系統或 QA/QC(品質保證/品質管制)措施,來幫助你們在產品出貨前就能抓到品質問題?
Andy Rasdal - CEO
Andy Rasdal - CEO
Sure. Well, we have had a lot of that before and I think maybe early in January provided a little bit more concrete update. As we got more data about that out of the box failure that we had attributed to simply being a sensor issue and without spending too much time, it really ended up being a mathematical parameter issue that either allows or doesn't allow the sensor to initialize. And the sensors that went in and were able to look at that it quote failed or it didn't initialize, were able to get data back from a number of patients, actually track glucose literally perfectly. And so it's just an old failsafe from a first generation product back in 2004, and so it more related to the software parameters, but is that related to being a PMA supplement to change such an algorithm? And the most immediate response was actually to tighten up the release criteria within final inspection to ensure the sensors could meet that.
當然。我們之前確實遇到過不少這類情況,我想也許在一月初我們提供過更具體的更新。隨著我們取得更多關於那次開箱即故障的資料——我們原本把它歸因於單純的感測器問題——不多花時間細談,最後發現其實是某個數學參數的問題:它會決定感測器是否允許初始化。那些裝上去後我們能回頭查看、被標示為「失敗」或「未初始化」的感測器,我們其實從多位病患那裡取回了數據,結果血糖追蹤幾乎是完全精準。因此,那只是源自 2004 年第一代產品的一個舊式保護機制(failsafe);所以它更與軟體參數相關。但這是否涉及以 PMA 補充申請來更改這種演算法?而最即時的回應其實是:在最終檢驗中收緊放行標準(release criteria),以確保感測器能符合要求。
And although that certainly caused some supply issues initially, it also forced the discipline to very rapidly tighten the distribution or the standard deviation of that product such that we could hit a tighter window. And so although the resolution of that related to how we did manufacturing, the fundamental issue was created by not unusually a first generation product design that relates back to 2004, and that parameter has already been changed and expanded in the seven-day product that's awaiting an FDA decision.
雖然這在一開始確實造成了一些供應問題,但它也迫使我們建立紀律,非常快速地收斂該產品的分布或標準差,使我們能落在更緊的區間內。因此,儘管解決方式與我們如何製造有關,根本原因其實來自一個並不罕見的第一代產品設計,且可追溯到 2004 年;而該參數在等待 FDA 決定的七天產品中已經被修改並放寬。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
And that was my last follow-up on the seven-day. Are there incremental improvements going into that product even [versus] the improvements you've been able to make to date on just a plain old manufacturing process that's going to allow you maybe get over some of these scale challenges you've seen. Inherent in the product itself.
這也是我對七天產品最後一個追問。相較於你們迄今僅透過一般製造流程所能做到的改善,七天產品本身是否還會加入額外的增量改良,讓你們也許能克服一些你們看到的規模化挑戰——也就是產品本身內建的改良?
Andy Rasdal - CEO
Andy Rasdal - CEO
Everything that we learned up and through even the first few months of commercialization was reflected in the PMA that we filed in Q2 of 2006 for the seven-day. And certainly as we spend this time in the hurry up and wait period, we continue to learn and we always look for opportunity to amend as appropriately, but many of the changes relate to manufacturing are 30 day manufacturing changes anyway, and you don't always pursue an appropriate path with the FDA. But often, once a PMA or a PMA supplement is improved, the 30 day path makes the most sense rather than delay the introduction of the new product that we think is important for patients.
我們在商業化初期、甚至前幾個月一路學到的所有內容,都已反映在我們於 2006 年第二季(Q2)為七天產品提交的 PMA 中。當然,在這段「趕快做完然後等待」(hurry up and wait)的期間,我們仍持續學習,也一直尋找適當修訂的機會;但許多與製造相關的變更本來就是 30 天製造變更,你不一定總是會走一條需要與 FDA 事先協調的適當路徑。不過通常,一旦 PMA 或 PMA 補充申請已經改善,走 30 天路徑往往最合理,而不是延後我們認為對病患很重要的新產品導入。
Operator
Operator
Brian Wong, First Albany Capital.
Brian Wong,First Albany Capital。
Brian Wong - Analyst
Brian Wong - Analyst
Just a couple of quick questions. First of all, you mentioned that you're out of your backlog, you've got products in inventory. I'm just trying to get a sense of if demand picks up, whether you're going to be able to meet that demand with the product you have in inventory.
我有幾個簡短問題。首先,你提到你們已清完積壓訂單(backlog),而且庫存裡有產品。我想了解的是,如果需求回升,你們是否能用現有庫存來滿足那個需求。
Andy Rasdal - CEO
Andy Rasdal - CEO
Well, I suppose in any dramatic non-linear change has the potential to impact supply, but we do have one, an inventory cushion, that will allow us to -- an inventory cushion more than ever that would allow us to absorb such a thing and I believe based upon the kind of yields and throughput improvements we've made, that would allow us to rather rapidly sort of respond if that -- a change was then sustained in a linear fashion.
嗯,我想任何劇烈的非線性變化都有可能影響供應,但我們確實有一個——庫存緩衝,能讓我們——比以往更充足的庫存緩衝,讓我們能吸收這種情況;而且我相信,基於我們在良率與產出(throughput)上的改善,如果那樣的變化之後以線性的方式持續下去,我們將能相當快速地做出回應。
So I'll never say never because I spend a lot of time scaling new products over a number of years, but I think we are in the best position ever. We have an inventory cushion. We have very robust processes and I think the ability to respond rapidly.
所以我永遠不會說「永不」,因為我花了很多時間在數年期間擴大量產新產品,但我認為我們正處於史上最佳的位置。我們有庫存緩衝。我們有非常健全的流程,而且我認為也具備快速應對的能力。
Brian Wong - Analyst
Brian Wong - Analyst
Then you mentioned yield percentages are around 75%.
接著你提到良率百分比大約在 75% 左右。
Andy Rasdal - CEO
Andy Rasdal - CEO
We said they had improved 75%.
我們說它們改善了 75%。
Brian Wong - Analyst
Brian Wong - Analyst
Oh, improved 75%.
喔,改善了 75%。
Andy Rasdal - CEO
Andy Rasdal - CEO
From where we ended December to where we are currently in this quarter.
從我們在 12 月底的水準到目前這一季的水準。
Brian Wong - Analyst
Brian Wong - Analyst
What are the yield percentages that you are seeing?
你們目前看到的良率百分比是多少?
Andy Rasdal - CEO
Andy Rasdal - CEO
We've never commented on those.
我們從未對那些數字發表評論。
Brian Wong - Analyst
Brian Wong - Analyst
Do you think there's additional room for improvement in the yields? Or is that pretty much at a steady state now where you are?
你認為良率還有進一步改善的空間嗎?還是說你們現在基本上已經處於穩態了?
Andy Rasdal - CEO
Andy Rasdal - CEO
Well, I think even a 99% yield, there's -- although it becomes asymptotic, there is certainly improvement in yields and often driving towards improvement in yields also drives a higher degree of reliability and performance in the product as you scale, so [you're going to] say certainly there is improvement in yields, but what we focus on are the fundamental improvements that drive yields and enhance (technical difficulty) increase substantially.
嗯,我認為即使良率達到 99%,仍然——雖然它會趨近漸近線——但良率當然還是可以改善;而且在擴大量產時,推動良率改善往往也會帶動產品更高程度的可靠性與效能。所以你會說良率確實還能改善,但我們關注的是能夠驅動良率的根本性改善,並提升(技術難度)大幅增加。
Brian Wong - Analyst
Brian Wong - Analyst
And then, you mentioned that you've got two out of your three processes automated. Are there any other areas or processes that you see going forward that could be automated that would improve significantly?
另外,你提到你們三個流程中已有兩個自動化。往後你們是否看到還有其他領域或流程可以自動化,並帶來顯著改善?
Andy Rasdal - CEO
Andy Rasdal - CEO
Well, I think the three big ones are clearly, for lack of a better description, kind of the bottlenecks on the line, the ones that require the most intensive people interaction in management. A number of the processes already were automated. In some cases, this is just further automation, but I think right now, these three we think have substantial opportunity to improve throughput and reduce the number of people required and allow us to scale very reliably. And so I think we'll focus on the two that have been approved by the FDA and making sure we implement those in a manner which doesn't jeopardize product quality and get the third one approved and implement that afterwards.
嗯,我認為三個最大的項目很明顯——如果要用更貼切的說法——就是產線上的瓶頸,也就是需要最密集人員互動與管理的那些環節。許多流程原本就已自動化;在某些情況下,這只是進一步自動化。但我認為目前我們認定這三項有很大的機會提升產出、降低所需人力,並讓我們能非常可靠地擴大量產。因此我想我們會先聚焦在已獲 FDA 核准的兩項,並確保以不危及產品品質的方式導入;同時讓第三項取得核准,之後再導入。
Brian Wong - Analyst
Brian Wong - Analyst
And then two more questions, if I may. In terms of your in-hospital products, I know you said you're looking to determine what that pathway would be, but would you be able to tell us whether that might be a 510-K or a PMA pathway?
如果可以的話再問兩個問題。就你們的院內產品而言,我知道你說你們正在評估可能的法規路徑,但你能否告訴我們那可能會是 510-K 還是 PMA 路徑?
Andy Rasdal - CEO
Andy Rasdal - CEO
We don't know the answer. I think it would be either a supplement to our current PMA or a 510 K, although I can definitively rule it out, I think [we] would be surprised if it required a whole new PMA, given that we are leveraging basically the same technology, the same clinical utility and so forth. So I think PMA supplement or 510 K would be where we would be leaning today.
我們不知道答案。我認為可能會是對我們現有 PMA 的補充申請(supplement),或是 510(k);雖然我無法斷言排除,但我想如果它需要一個全新的 PMA,我們會感到意外,因為我們基本上是在沿用相同的技術、相同的臨床效用等等。所以我認為以今天來看,我們會傾向於 PMA 補充申請或 510(k)。
Brian Wong - Analyst
Brian Wong - Analyst
And the last question is for Steve. Could you give us a sense of what the stock options expensing cost was for the quarter?
最後一個問題給 Steve。你能否讓我們了解一下本季股票選擇權費用化的成本是多少?
Steve Kemper - CFO
Steve Kemper - CFO
Yes, it's been running about $1.5 million to $1.6 million per quarter.
可以,近來每季大約在 150 萬到 160 萬美元。
Operator
Operator
Mimi Pham, HSBC.
HSBC 的 Mimi Pham。
Mimi Pham - Analyst
Mimi Pham - Analyst
You mentioned before that you focused on the top 45 or 50 centers. Are you still focused on just these? And ultimately, how many top centers do you plan to support?
你之前提到你們聚焦在前 45 或 50 家中心。你們現在仍只聚焦在這些中心嗎?最終你們計畫支援多少家頂尖中心?
Andy Rasdal - CEO
Andy Rasdal - CEO
Well, we had I think said earlier in January that even without product and one of the activities for people if you don't have product driving your customers is certainly do the selling via education and training at the centers. We don't have the personalities in the field that want to sit around and play golf. These are hard charging, well motivated folks, and so we have always sort of trickled well beyond the 40 or 50 because of just the need to serve patients that have real needs, although the strategic focus has been and continues to be on the top 40 to 50, especially why we operate in an environment that we have today, but we've expanded [two] more, and I think the goal is ultimately with 40 plus people in the field, we can support substantially more than the 40 to 50 and we just want to make sure that we've got things well sold, the people truly see the value of it and are prescribing and training on their own before we just expand to get additional one-off patients.
嗯,我想我們在 1 月稍早曾說過,即使沒有產品——如果你沒有產品可供推動客戶,其中一項人員活動當然就是透過在中心進行教育與訓練來做銷售。我們外勤團隊不是那種想坐著打高爾夫的人;他們衝勁十足、動機強。因此我們一直都會因應病患的實際需求,把服務範圍逐步擴展到 40 或 50 家之外,因為確實有病患有真實需求;不過策略重點一直是、也仍然是放在前 40 到 50 家,尤其是在我們目前所處的環境下。但我們又擴增了 [兩] 家;而我認為最終目標是,當外勤人員超過 40 人時,我們可以支援遠多於 40 到 50 家中心。我們只是想確保我們把事情賣得很到位,讓大家真正看見其價值,並且在我們擴展去服務更多零星個案之前,醫護端已能自行開立處方並進行訓練。
Mimi Pham - Analyst
Mimi Pham - Analyst
And then on the seven-day sensor, you mentioned some people are waiting for the seven-day sensor. Are you hearing this from patients directly or is this is more from the endocrinologist?
接著關於七天感測器,你提到有些人正在等待七天感測器。你們是直接從病患那裡聽到的,還是更多是從內分泌科醫師那裡聽到的?
Andy Rasdal - CEO
Andy Rasdal - CEO
I would say it's really from all data sources. We hear it from the educators, the endocrinologist, and patients. All, I would say.
我會說其實來自所有資料來源。我們從衛教師、內分泌科醫師以及病患那裡都聽到。我會說全部都有。
Mimi Pham - Analyst
Mimi Pham - Analyst
Can you just clarify when do you start actually ramping up your seven-day sensor manufacturing? As soon as you -- will it be ready then as soon as you get approval you can fully supply to customers?
你能否釐清一下你們何時會開始真正拉升七天感測器的製造?也就是說,一旦你們——在取得核准後就能立刻全面供應客戶嗎?
Andy Rasdal - CEO
Andy Rasdal - CEO
Well, certainly the intent as we demonstrated the three day is to supply and begin launching what we think is a meaningful second generation product as shortly after approval as we can get. We did that I think with the three day. Certainly that's the goal with the seven-day and a lot of that's determined by the FDA. As the product will share the same manufacturing lines, fundamental processes, equipment and operators, as we get approval, we can begin to make sensors fairly rapidly by just switching lines over almost instantaneously, and so that would be the goal is to certainly -- as we get further in discussions and have some clarity about when and if approval may come is begin to take a little bit, begin to put a little bit on the shelf, but I think our manufacturing and the continuity of the product is such that we can respond pretty rapidly once we do get approval.
嗯,當然,我們的意圖就如同我們在三天產品上所展現的,是在核准後盡可能快地供應並開始推出我們認為具重大意義的第二代產品。我想我們在三天產品上就是這麼做的。七天產品當然也是同樣目標,而其中很大一部分取決於 FDA。由於該產品將共用相同的製造產線、基本流程、設備與操作人員,一旦取得核准,我們幾乎可以透過幾乎即時地切換產線來相當快速地開始製造感測器;因此目標就是——當我們在討論中更深入、對核准可能何時以及是否會到來更有把握時,就開始先做一點、先放一點庫存。但我認為我們的製造能力與產品的連續性,使得我們一旦取得核准就能相當快速地回應。
Mimi Pham - Analyst
Mimi Pham - Analyst
Last question. How will you modify or change your sales and marketing approach once Abbott and Medtronic launch their systems?
最後一個問題。當 Abbott 和 Medtronic 推出他們的系統後,你們將如何調整或改變你們的銷售與行銷方式?
Andy Rasdal - CEO
Andy Rasdal - CEO
Well, I think we'll wait until those systems launch. Certainly, we certainly welcome more help into the marketplace about driving the message of continuous glucose monitoring and making these technologies more widely available to the people and the caregivers who can benefit from them.
嗯,我想我們會等那些系統推出之後再看。當然,我們也歡迎有更多夥伴進入市場,協助推動連續血糖監測的訊息,並讓這些技術更廣泛地提供給能從中受益的人以及照護者。
Operator
Operator
Steve Ogilvie, ThinkEquity.
ThinkEquity 的 Steve Ogilvie。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
A question on the cost of goods sold, could you maybe explain when, what the revenue run rate needs to be to have positive gross margins and how that changes with the seven- day?
關於銷貨成本(COGS)的一個問題:你能否說明一下,要達到正毛利率,營收的運行速率需要到什麼程度?以及在七天產品下這會如何改變?
Andy Rasdal - CEO
Andy Rasdal - CEO
We've not giving any kind of guidance related to that specifically, and it's fairly dynamic even at this. Relative to the seven-day, as we said, we would expect to set prices higher for the value we bring on a per day basis for the seven-days, not linear in line with the three day product but somewhere between those two. And we -- of course, it's an evolving marketplace and we've not set product yet, but given that the product is very similar and utilizes the same manufacturing machines and processes, any increase in price should be additional contribution margin and accelerate the path towards breakeven.
我們沒有就此提供任何具體指引,而且即使在目前階段也相當動態。就七天產品而言,如我們所說,我們預期會就七天產品在「每一天」所帶來的價值設定較高的價格,不會與三天產品呈線性對應,而是介於兩者之間。當然,市場仍在演變,我們也尚未設定產品(價格),但鑑於該產品非常相似,且使用相同的製造機台與流程,任何價格的提高都應會帶來額外的貢獻毛利,並加速走向損益兩平的進程。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
And then maybe ask from a different direction, just trying to understand how much of the cogs in the last couple of quarters is due to the improving -- or lowering your yields and improving the quality control. Is a bit of that going to fall off assuming that the seven-day doesn't have any issues?
那我換個角度問,想了解一下,過去幾季的銷貨成本中,有多少是因為——改善或降低你們的良率並提升品質控管所造成的?如果假設七天產品沒有任何問題,這部分是否會下降?
Steve Kemper - CFO
Steve Kemper - CFO
Well, as we mentioned that we worked on all those problems and challenges throughout the third and fourth quarter and as Andy mentioned, we saw a good yield improvement toward the end of December and into January, so as I mentioned in my comments, we expect to see better absorption going forward. Obviously, as you're building more product that is earned into inventory, that's going to be positive toward your cost of goods sold line.
嗯,正如我們提到的,我們在第三季與第四季期間一直在處理那些問題與挑戰;而且如 Andy 所說,我們在 12 月底到 1 月期間看到良率有不錯的改善。因此如我在評論中提到的,我們預期未來會看到更好的吸收率。顯然,當你生產更多產品並將其計入庫存時,這會對你的銷貨成本項目帶來正面影響。
Andy Rasdal - CEO
Andy Rasdal - CEO
I think the other thing, Steve, certainly we've made substantial yield improvements and I think that reflects of course in lower-cost, but I think that the next phase of that, as I said, is further automation that falls in line with Steve, that drives greater volume through an existing facility or line with less labor. And I think we've been very methodical about that, having done it, it's easy to say automate, but if you are making marginal product and you automate, you just make more marginal product. And our (indiscernible) to ensure that we are making good product and that we're doing it on purpose and then to phase in volume increases or automation to do that. And so if we start to cap off of getting cost improvements out of the yields, then we'd expect to see some improvements based upon automation and further process development.
我想另一件事,Steve,當然我們已經在良率方面做出了顯著改善,我認為這當然反映在較低的成本上;但我認為下一階段,如我所說,是進一步的自動化,這也與 Steve 的方向一致,也就是在現有的廠房或產線上,以更少的人力推動更大的產量。我認為我們在這方面一直非常有條不紊;做過之後很容易說要自動化,但如果你做的是邊際產品而去自動化,你只會做出更多邊際產品。我們的(聽不清)是要確保我們做的是好產品,而且是有目的地在做,然後再分階段導入產量提升或自動化來達成。因此,如果我們開始在良率帶來的成本改善上見頂,我們預期會看到一些基於自動化與進一步製程開發所帶來的改善。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
And then is there any technical reason for a diabetic to wait for the seven-day? And are you going to aggressively market against that or are you just going to kind of wait and bide your time until the seven-day comes, because it's not pushing the three day when the seven-day is coming?
那麼,對於糖尿病患者而言,有沒有任何技術上的原因需要等到七天款?你們會積極針對那點做行銷,還是你們會先觀望、等待七天款推出,因為既然七天款要來了,就不會去推三天款?
Andy Rasdal - CEO
Andy Rasdal - CEO
Well, there's no clinical or technical reason, but I know a whole lot of people who never buy a new car in its first model year, and clearly, I think not unexpectedly, we see that and as word spreads that timelines are getting closer; that's kind of a natural response and I would suffice it to say that we've got a very experienced, creative and motivated field force that I believe will deal with that objection real-time. Nonetheless, we do hear it.
嗯,沒有臨床或技術上的原因,但我認識很多人從不在新車第一個車型年度就購買;而且很明顯地,我認為不出所料,我們也看到了這種情況。隨著消息傳開、大家知道時程越來越近,這是一種自然反應。我想我可以說的是,我們有一支非常有經驗、富創意且充滿動力的前線團隊,我相信他們會即時處理這類反對意見。儘管如此,我們確實有聽到這樣的聲音。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
But if someone bought a three day today, they're not out of luck when the seven-day comes. They can switchover easy enough?
但如果有人今天買了三天款,等七天款推出時也不會吃虧。他們可以很容易切換過去?
Andy Rasdal - CEO
Andy Rasdal - CEO
Yes, but they'll have to be on the seven-day system to gain all of the benefits from the seven-day system. We will, of course, work with good customers to make sure those upgrades are done effectively, but yes.
是的,但他們必須使用七天系統,才能獲得七天系統的所有效益。我們當然會與優質客戶合作,確保這些升級能有效完成,但答案是肯定的。
Operator
Operator
Alex Arrow, Lazard Capital Markets.
Alex Arrow,Lazard Capital Markets。
Alex Arrow - Analyst
Alex Arrow - Analyst
Andy, on the guidance that you gave for the current quarter revenues coming in, I believe but it was similar to the way the third quarter and the fourth quarter has been when there was a supply constraint. Can you help us understand if the supply constraint has been largely or completely eliminated as of January 15? And the sales reps that have the last couple of quarters to do the educating of the docs and patients, why is it that the guidance is for a similar level of revenue as third quarter, fourth quarter?
Andy,關於你對本季營收的指引,我記得它看起來與第三季、第四季在供應受限時的情況相似。你能否協助我們理解,截至 1 月 15 日,供應限制是否已大致或完全解除?而且銷售代表在過去幾季已經做了醫師與病患的教育,為什麼指引仍是與第三季、第四季相近的營收水準?
Andy Rasdal - CEO
Andy Rasdal - CEO
Well, I think we, what we've seen, I don't know if it's guidance, but it's the best that we can give at this point is the run rates are similar in all aspects and I think, as I said, I think if I listen to the sales reps and I spent a lot of time with it, that certainly after we weren't able to fulfill customer orders and sales rep demand in Q3 and 4, as well as some of the center performance issues, that patients are going -- or physicians are going to put a handful of patients on those, see how they do, make sure that they work and patients are happy with them and that they can be appropriately supported before they expand, and that takes more than just one or two weeks. And so I think it's realistic to expect that after you do that, that there's some time to sort of restart the channel. Clearly we're trying to re-create the experiences, but as we said, unless those rates accelerate and I'm optimistic that the product availability and the product performance and the capabilities of our field force has a good chance to impact that. Based upon where the run rates are today, I can't tell you that they are up.
嗯,我想我們所看到的——我不確定那算不算指引——但就目前而言,我們能給出的最好說法是,各方面的運行速率都相近。我想如我所說,如果我聽銷售代表的回饋(我也花了很多時間在這上面),在我們於第三季與第四季無法滿足客戶訂單與銷售代表需求之後,再加上一些中心端的表現問題,病患——或醫師——會先讓少數幾位病患使用,看看效果如何,確認產品確實有效、病患也滿意,並且在擴大之前能得到適當支援;而這需要的不只是短短一兩週。因此我認為,做完這些之後,通路要重新啟動確實需要一些時間。很明顯我們正努力重建這些體驗,但如我們所說,除非那些速率加快——我對產品供應、產品表現以及我們前線團隊的能力能夠帶來影響抱持樂觀——但以目前的運行速率來看,我無法告訴你它們已經上升。
Alex Arrow - Analyst
Alex Arrow - Analyst
On Abbott, I know they've been saying that they're about to launch for quite some time now. Are you hearing from the field that (indiscernible) are beginning to get frustrated or they feel more or less the same about the navigator as they did before? Any color you can give us on the Abbott situation?
關於 Abbott,我知道他們一直說他們快要上市了,已經說了一段時間。你們從前線聽到的是(聽不清)開始感到挫折,還是他們對 Navigator 的看法大致與之前相同?你能否就 Abbott 的情況提供一些補充說明?
Andy Rasdal - CEO
Andy Rasdal - CEO
I don't really think it's our place to provide any sort of just general feedback from the field that is substantial to rumor. I think to best comment that would be Abbott. Certainly in a new category, several good competitors, all out to help patients and driving the category are welcome and important in moving this thing forward. But we don't hear anything outside of the commentary that they've had on their calls and where they've guiding specifically related to the Navigator product.
我不認為由我們來提供任何來自前線、但本質上會助長傳聞的概括性回饋是合適的。要評論這點,Abbott 會是最適合的。當然,在一個新類別中,有幾個優秀競爭者,大家都希望幫助病患並推動類別發展,這是受歡迎且重要的,有助於推動事情向前。但我們沒有聽到任何超出他們在電話會議上的評論,以及他們對 Navigator 產品所做的具體指引之外的訊息。
Alex Arrow - Analyst
Alex Arrow - Analyst
And on the [hixpix] code, the processes you described is that Medtronic and DexCom have both applied, did Abbott then become part of the process as well? Can you help us understand what impact Abbott might have on the [hixpix]?
再問關於 [hixpix] 代碼,你描述的流程是 Medtronic 和 DexCom 都已提出申請,那 Abbott 是否也成為流程的一部分?你能否協助我們理解 Abbott 可能會對 [hixpix] 造成什麼影響?
Andy Rasdal - CEO
Andy Rasdal - CEO
Well, probably Abbott would be the best commentary on that. Certainly my understanding is that you have to have FDA approval to actually file an application and that would leave us and Medtronic, but in the same way that we didn't have that in 2000 -- at the end of 2005 and we essentially became party with Medtronic's [hixpix] application through the open hearings, through some of the Congressional hearings and through [IMCAC] and some of those other things, as Abbott brings their product forward, I would imagine with their history, they would play an important, meaningful role in that process as well.
嗯,這方面 Abbott 可能是最適合評論的。當然,我的理解是,你必須先取得 FDA 核准才能真正提出申請,這樣就只剩我們和 Medtronic;但就像我們在 2000——在 2005 年底時並沒有那個條件一樣,我們基本上是透過公開聽證會、一些國會聽證會、以及 [IMCAC] 和其他一些機制,成為 Medtronic 的 [hixpix] 申請案的參與方。隨著 Abbott 推進他們的產品,我想以他們的歷史來看,他們也會在該流程中扮演重要且具實質意義的角色。
Andy Rasdal - CEO
Andy Rasdal - CEO
All right. Great. Thank you very much. That ends our call.
好的。很好。非常感謝。今天的電話會議到此結束。
Operator
Operator
And again we'd like to thank everyone for your participation in today's conference call and wish everyone a good day.
再次感謝各位參與今天的電話會議,並祝各位有美好的一天。